TRIFLUOPERAZINE vs placebo: Global state ‐ relapse or worsening ‐ medium term Numbers of participants experiencing relapse/worsening
TRIFLUOPERAZINE may leads to lower global state ‐ relapse or worsening ‐ medium term Numbers of… compared with PLACEBO (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
TRIFLUOPERAZINE vs PLACEBO Global state ‐ relapse or worsening ‐ medium term Numbers of participants experiencing relapse/worsening · patients with schizophrenia TRIFLUOPERAZINE may leads to lower global state ‐ relapse or worsening ‐ medium term Numbers of… compared with PLACEBO (low certainty). Trifluoperazine versus placebo for schizophrenia (2014) · Cochrane Headline outcomes only | RR 0.34 [0.23, 0.49] | 2 studies · 381 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Trifluoperazine versus placebo for schizophrenia 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.